CorMedix Inc. (NYSE American: CRMD) Attends 31st Annual ROTH Conference
CorMedix (NYSE American: CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is developing its lead product Neutrolin, a novel non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Neutrolin is currently in phase 3 development for patients undergoing chronic hemodialysis. Neutrolin has FDA Fast Track status and is already marketed as a CE Marked product in Europe and other territories. For more information, visit the company's website at www.cormedix.com. About NetworkNewsWire NetworkNewsWire (NNW) is…







